KRAS and pancreatic neuroendocrine tumor: Furthermore, KRAS mutations – a driver gene more prevalent in pancreatic ductal adenocarcinoma – are also observed in some PNEC cases, potentially promoting rapid growth and drug resistance.[38] Conversely, MEN1 mutations, common in well-differentiated pancreatic neuroendocrine tumors, are extremely rare in PNEC, highlighting the distinct genetic origins of these 2 tumor entities.[38] Our prognostic model, developed based on age, differentiation grade, and metastatic patterns, would significantly enhance predictive accuracy if integrated with such molecular data.